Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities

ClinicalTrials.gov ID: NCT04683250

Public ClinicalTrials.gov record NCT04683250. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 16, 2026, 8:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase I/II Study of the Selective RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities

Study identification

NCT ID: NCT04683250
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Taiho Pharmaceutical Co., Ltd.; Industry
Enrollment: 244 participants

Conditions and interventions

Conditions

Interventions

TAS0953/HM06 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 15, 2020
Primary completion: Feb 28, 2030
Completion: Feb 28, 2031
Last update posted: Mar 2, 2026

2020 – 2031

United States locations

U.S. sites: 9
U.S. states: 6
U.S. cities: 8

Facility	City	State	ZIP	Site status
Chao Family Comprehensive Cancer Center	Orange	California	92868-3298	Terminated
Stanford Cancer Center	Stanford	California	94305-5826	Terminated
Massachusetts General Hospital	Boston	Massachusetts	02114	Terminated
Henry Ford Hospital	Detroit	Michigan	48202	Terminated
START Midwest - Cancer & Hematology Centers of Western Michigan	Grand Rapids	Michigan	49546	Terminated
Laura and Isaac Perlmutter Cancer Center at NYU Langone Health	New York	New York	10016	Terminated
Memorial Sloan Kettering Cancer Center	New York	New York	10065	Terminated
The Sarah Cannon Research Institute/Tennessee Oncology	Nashville	Tennessee	37203	Terminated
The University of Texas M. D. Anderson Cancer Center	Houston	Texas	77030-4009	Terminated

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 12 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT04683250, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Mar 2, 2026 · Synced May 16, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04683250 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →